deferoxamine has been researched along with Triple Negative Breast Neoplasms in 3 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine treatment decreased intracellular iron, suppressed nuclear factor-κB activation, and induced apoptosis." | 1.51 | The Role of Deferoxamine in Irradiated Breast Reconstruction: A Study of Oncologic Safety. ( Buchman, SR; Cohen, MS; Donneys, A; Lynn, JV; Nelson, NS; Ranganathan, K; Subramanian, C; Urlaub, KM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C | 1 |
| Wang, S | 1 |
| Liu, P | 1 |
| Goto, W | 1 |
| Kashiwagi, S | 1 |
| Asano, Y | 1 |
| Takada, K | 1 |
| Morisaki, T | 1 |
| Takahashi, K | 1 |
| Fujita, H | 1 |
| Shibutani, M | 1 |
| Amano, R | 1 |
| Takashima, T | 1 |
| Tomita, S | 1 |
| Hirakawa, K | 1 |
| Ohira, M | 1 |
| Lynn, JV | 1 |
| Urlaub, KM | 1 |
| Ranganathan, K | 1 |
| Donneys, A | 1 |
| Nelson, NS | 1 |
| Subramanian, C | 1 |
| Cohen, MS | 1 |
| Buchman, SR | 1 |
3 other studies available for deferoxamine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism.
Topics: Cell Line, Tumor; Cell Movement; Cell Survival; Deferoxamine; Female; Humans; Iron; MCF-7 Cells; Mit | 2019 |
Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Topics: Animals; Antigens, CD; B7-H1 Antigen; Cadherins; Cell Cycle; Cell Line, Tumor; Deferasirox; Deferoxa | 2020 |
The Role of Deferoxamine in Irradiated Breast Reconstruction: A Study of Oncologic Safety.
Topics: Analysis of Variance; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferoxamine; | 2019 |